RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Basi molecolari, aspetti fisiopatologici e terapeutici delle malattie lisosomiali
• 2 - Patogenesi molecolare delle malattie del motoneurone come tool per l’identificazione di nuovi approcci terapeutici biomolecolari e cellulari
• 3 - Intolleranza alle proteine con lisinuria: sviluppo ed analisi di un modello genetico murino di tipo condizionale e di modelli cellulari umani
• 4 - Segnali e dialogo fra cellule neuronali, gliali e muscolari nella sclerosi laterale amiotrofica
• 5 - Reattività oligodendrogliale e meccanismi riparativi in modelli murini del morbo di Alzheimer
• 6 - Studi struttura-funzione sulle neurotrofine e loro precursori nella funzione presinaptica, nella epilettogenesi e nella neurogenesi adulta
• 7 - screening di farmaci su un modello animale di zebrafish per la Chorea di Huntington
• 8 - Meccanismi cellulari e molecolari di morte e protezione neuronale
• 9 - Studi funzionali del ritardo mentale legato al cromosoma X in modelli in vivo ed in vitro
• 10 - BETA AMILOIDE: IL PRINCIPALE RESPONSABILE DELLA NEURODEGENERAZIONE NELLA MALATTIA DI ALZHEIMER O UN NUOVO NEUROMODULATORE?

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze biologiche
  • FISIOLOGIA
  • BIOCHIMICA
  • BIOLOGIA MOLECOLARE
  • BIOLOGIA APPLICATA
  • FARMACOLOGIA

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material A01N63/00; food compositions A21, A23; medicinal preparations A61K; chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles A61L; fertilisers C05); PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS (preservation of living parts of humans or animals A01N1/02); MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (micro-biological testing media C12Q)
• HUMAN NECESSITIES
  • AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

Classificazione geografica

• Regione: Toscana

Bibliografia

Alberi L., Sgado P. and Simon H.H. (2004). Engrailed genes are cell-autonomously required to prevent apoptosis in mesencephalic dopaminergic neurons. Development 131, 3229-3236.
Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., et al. (2000). Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3, 1301-1306.
Bonifati V., Breedveld G.J., Squitieri F., Vanacore N., Brustenghi P., et al. (2002). Localization of autosomal recessive early-onset parkinsonism to chromosome 1p36 (PARK7) in an independent dataset. Ann Neurol 51, 253-256.
Corsini, G.U., R. Maggio and F. Vaglini. (2002). Molecular and cellular events regulating dopamine neuron survival. In Handbook of Experimental Pharmacology. Dopamine in the CNS II. (ed. Chiara, G.D.), pp. Vol 154, 321-386. Springer-Verlag, Berlin Heidelberg.
Dunnett S.B. and Bjorklund A. (1999). Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 399, A32-9.
Fahn S. (2003). Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci 991, 1-14.
Feany M.B. and Bender W.W. (2000). A Drosophila model of Parkinson's disease. Nature 404, 394-398.
Funayama M., Hasegawa K., Kowa H., Saito M., Tsuji S., et al. (2002). A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 51, 296-301.
Gerfen C.R. (2000). Molecular effects of dopamine on striatal-projection pathways. Trends Neurosci 23, S64-70.
Giasson B.I., Duda J.E., Quinn S.M., Zhang B., Trojanowski J.Q., et al. (2002). Neuronal alpha-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human alpha-Synuclein. Neuron 34, 521-533.
Goldberg M.S., Fleming S.M., Palacino J.J., Cepeda C., Lam H.A., et al. (2003). Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 278, 43628-43635.
Healy D.G., Abou-Sleiman P.M. and Wood N.W. (2004). Genetic causes of Parkinson's disease: UCHL-1. Cell Tissue Res 318, 189-194.
Holzmann C., Kruger R., Saecker A.M., Schmitt I., Schols L., et al. (2003). Polymorphisms of the alpha-synuclein promoter/ expression analyses and association studies in Parkinson's disease. J Neural Transm 110, 67-76.
Itier J.M., Ibanez P., Mena M.A., Abbas N., Cohen-Salmon C., et al. (2003). Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet 12, 2277-2291.
Jeon B.S., Jackson-Lewis V. and Burke R.E. (1995). 6-Hydroxydopamine lesion of the rat substantia nigra/ time course and morphology of cell death. Neurodegeneration 4, 131-137.
Jiang C., Wan X., He Y., Pan T., Jankovic J., et al. (2005). Age-dependent dopaminergic dysfunction in Nurr1 knockout mice. Exp Neurol 191, 154-162.
Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., et al. (1998). Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608.
Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., et al. (1998). Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18, 106-108.
Kuopio A., Marttila R.J., Helenius H. and Rinne U.K. (2001). Familial occurrence of Parkinson's disease in a community-based case-control study. Parkinsonism Relat Disord 7, 297-303.
Langston J.W., Ballard P., Tetrud J.W. and Irwin I. (1983). Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979-980.
Le W., Conneely O.M., Zou L., He Y., Saucedo-Cardenas O., et al. (1999). Selective agenesis of mesencephalic dopaminergic neurons in Nurr1- deficient mice. Exp Neurol 159, 451-458.
Le W.D., Xu P., Jankovic J., Jiang H., Appel S.H., et al. (2003). Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet 33, 85-89.
Lee M.K., StirlingW., Xu Y., Xu X., Qui D., et al. (2002). Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A 99, 8968-8973.
Leroy E., Boyer R., Auburger G., Leube B., Ulm G., et al. (1998). The ubiquitin pathway in Parkinson's disease. Nature 395, 451-452.
Liu A. and Joyner A.L. (2001). EN and GBX2 play essential roles downstream of FGF8 in patterning the mouse mid/hindbrain region. Development 128, 181-191.
McNaught K.S., Perl D.P., Brownell A.L. and Olanow C.W. (2004). Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 56, 149-162.
Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J., et al. (2004). Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600.
Perese D.A., Ulman J., Viola J., Ewing S.E. and Bankiewicz K.S. (1989). A 6-hydroxydopamine-induced selective parkinsonian rat model. Brain Res 494, 285-293.
Piccini P., Burn D.J., Ceravolo R., Maraganore D. and Brooks D.J. (1999). The role of inheritance in sporadic Parkinson's disease/ evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 45, 577-582.
Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., et al. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
Przedborski S., Jackson-Lewis V., Naini A.B., Jakowec M., Petzinger G., et al. (2001). The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J Neurochem 76, 1265-1274.
Ricaurte G.A., Irwin I., Forno L.S., DeLanney L.E., Langston E., et al. (1987). Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra. Brain Res 403, 43-51.
Seniuk N.A., Tatton W.G. and Greenwood C.E. (1990). Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP. Brain Res 527, 7-20.
Simon H.H., Saueressig H., Wurst W., Goulding M.D. and O'Leary D.D. (2001). Fate of midbrain dopaminergic neurons controlled by the engrailed genes. J Neurosci 21, 3126-3134.
Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., et al. (2003). alpha-Synuclein locus triplication causes Parkinson's disease. Science 302, 841.
Sgadò P., Albéri L., Galasso S.L., Ramakers G.M.J., Smidt M.P., Dyck R.H. and Simon H.H. Progressive postnatal degeneration of nigral dopaminergic neurons in Engrailed mutant mice. Science, submitted.
Uversky V.N. (2004). Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res 318, 225-241.
Vieregge P. (1994). Genetic factors in the etiology of idiopathic Parkinson's disease. J Neural Transm Park Dis Dement Sect 8, 1-37.
Von Coelln R., Thomas B., Savitt J.M., Lim K.L., Sasaki M., et al. (2004). Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proc Natl Acad Sci U S A 101, 10744-10749.
Von Coelln R., Dawson V.L. and Dawson T.M. (2004). Parkin-associated Parkinson's disease. Cell Tissue Res 318, 175-184.
Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., et al. (2004). Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601-607.

Parole Chiave

MALATTIA DI PARKINSON; GENI ENGRAILED; AMINE BIOGENE; CAUDATO-PUTAMEN